Navigation Links
Herpes drug inhibits HIV in patients infected with both viruses
Date:9/15/2008

This release is available in French.

Researchers at the U.S. National Institutes of Health (NIH), McGill University and other institutions have discovered how a simple antiviral drug developed decades ago suppresses HIV in patients who are also infected with herpes. Their study was published in the Sept. 11 issue of the journal Cell Host and Microbe.

An NIH research team led by Dr. Leonid Margolis made the initial discovery, while Dr. Matthias Gotte, Associate Professor in Biochemical Virology at McGill's Department of Microbiology and Immunology, along with colleagues at Emory University, helped explain the precise molecular mechanisms.

According to Dr. Gotte, HIV/herpes co-infection rates are very high and carry significant health burdens for those patients who are already coping with HIV.

"In co-infected individuals, HIV disease progression is enhanced by the presence of herpes," he explained. "Why this is the case is not clear, but there's a lot of evidence for it. Moreover, if you're infected with HIV and herpes, it makes it easier for you to transmit HIV to other people. And if you're infected with herpes alone, it makes it easier for you to acquire HIV."

Though it was long-believed that acyclovir was an ineffective drug against HIV, it was often prescribed to co-infected patients in the hope of indirectly treating HIV by reducing the herpes load. Surprisingly, the NIH team discovered that in the presence of herpes virus HHV-6, acyclovir actually attacks HIV directly and is able to suppress its reproduction.

Acyclovir is a "prodrug," which is converted into its active form only after it is administered to a patient. The research team demonstrated that the herpes virus contains an enzyme not present in HIV and it is this enzyme that converts acyclovir into a compound capable of attacking in HIV. Acyclovir by itself is simply inactive against HIV and therefore the drug can only work in people infected with both viruses.

The researchers are hopeful this discovery may open a new front in the war on HIV, particularly in parts of the developing world where rates of co-infection are extremely high.

"No anti-retroviral kills HIV completely," Dr. Gotte said. "We need to administer at least three drugs to hold it in check. This potentially gives us another weapon in the armory, and it's cheap and accessible, which matters a lot in the developing world."


'/>"/>

Contact: Mark Shainblum
mark.shainblum@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related biology news :

1. Herpes virus link to complications in pregnancy
2. Penn researchers shine the light of venus to learn how the herpes virus invades cells
3. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
4. Majority of osteoporosis patients not receiving calcium and vitamin D with treatment
5. A home early warning system for cardiac patients
6. New sensory devices will aid Parkinsons and stroke patients
7. Unlocking mystery of why dopamine freezes Parkinsons patients
8. CMV infections affect more than just patients with compromised immune systems, researchers find
9. Smothered genes combine with mutations to yield poor outcome in cancer patients
10. Cross fire from the brain makes patients tremble
11. New treatment approach promising for lymphoma patients in the developing world
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology: